Nuvation Bio (NUVB) vs uniQure N.V. (QURE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nuvation Bio (NUVB) has outperformed uniQure N.V. (QURE) over the past year, gaining 33.1% versus a loss of 62.4%. Over five years, QURE leads with a -25.0% price change compared with -48.2% for NUVB. Nuvation Bio is the larger company by market cap ($1.75 billion vs $1.57 billion), about 1.1 times the size.
Nuvation Bio converts more of its revenue into profit, with a net margin of -325.3% versus -1236.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NUVB | QURE |
|---|---|---|
| Share price | $4.97 | $22.63 |
| Market cap | $1.75B | $1.57B |
| 1-day change | +0.40% | +0.38% |
| YTD return | -44.75% | -5.81% |
| 1-year return | +33.06% | -62.41% |
| 5-year return | -48.17% | -25.02% |
| EPS (TTM) | $-0.44 | $-4.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $62.90M | $16.10M |
| Revenue growth (YoY) | +698.96% | -40.64% |
| Net income (latest FY) | $-204.63M | $-198.97M |
| Gross margin | — | 89.53% |
| Operating margin | -338.72% | -1151.38% |
| Net margin | -325.31% | -1236.00% |
| 52-week high | $9.75 | $71.50 |
| 52-week low | $3.36 | $8.73 |
| Distance from 52-week high | -49.03% | -68.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +161.57% | +175.49% |
| Average volume | 5.65M | 1.97M |
| Shares outstanding | 350.12M | 69.37M |
| Employees | 305 | 221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NUVB has outperformed QURE by 95.5 percentage points over the past year.
- Nuvation Bio is more profitable, keeping -325.3 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
- Nuvation Bio grew revenue faster in its latest fiscal year (+698.96% vs -40.64%).
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 305 employees
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
NUVB vs QURE FAQ
Which is bigger, Nuvation Bio or uniQure N.V.?
Nuvation Bio (NUVB) is larger, with a market capitalization of $1.75B compared with $1.57B for uniQure N.V. (QURE).
Which stock has performed better over the past year, NUVB or QURE?
NUVB returned +33.06% over the past 12 months, compared with -62.41% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are Nuvation Bio and uniQure N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.